Literature DB >> 7447424

Effect of prednisolone and rifampin on isoniazid metabolism in slow and rapid inactivators of isoniazid.

G R Sarma, S Kailasam, N G Nair, A S Narayana, S P Tripathy.   

Abstract

The effect of prednisolone and rifampin, alone and in combination, on the biodisposition of isoniazid in slow and rapid inactivators of isoniazid was investigated. In one investigation, we made serial determinations of plasma isoniazid concentrations up to 8 h and of isoniazid and acetylisoniazid in excreted urine up to 8.5 h in patients receiving isoniazid alone on one occasion and isoniazid plus prednisolone or isoniazid plus rifampin on another. Prednisolone caused a significant decrease in the plasma isoniazid concentrations in both slow and rapid inactivators. It also enhanced the renal clearance of isoniazid in both slow and rapid inactivators and increased the rate of acetylation of isoniazid in slow inactivators only. Rifampin had no effect on the biodisposition of isoniazid in either slow or rapid inactivators. In a second investigation, one group of slow and rapid inactivators received isoniazid and rifampin, and a different group received prednisolone, in addition. Plasma isoniazid concentrations in slow inactivators receiving prednisolone were significantly lower than in those who received isoniazid and rifampin only. In rapid inactivators, plasma isoniazid concentrations were similar in the two groups of patients, suggesting that concomitant administration of rifampin had considerably modified the prednisolone effect on the biodisposition of isoniazid in these patients.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7447424      PMCID: PMC284072          DOI: 10.1128/AAC.18.5.661

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  [The effects of antituberculosis drugs on the pharmacokinetics of digitoxin (author's transl)].

Authors:  U Peters; T U Hausamen; F Grosse-Brockhoff
Journal:  Dtsch Med Wochenschr       Date:  1974-11-22       Impact factor: 0.628

2.  A modified method for the estimation of acetylisoniazid in urine.

Authors:  G R Sarma; C Immanuel; S Kailasam; M Kannapiran; N G Nair; S Radhakrishna
Journal:  Indian J Med Res       Date:  1974-06       Impact factor: 2.375

3.  Serum concentration and half-life of rifampicin after simultaneous oral administration of aminosalicylic acid or isoniazid.

Authors:  G Boman
Journal:  Eur J Clin Pharmacol       Date:  1974       Impact factor: 2.953

4.  Determination of the acetylator phenotype from the ratio of the urinary excretion of acetylisoniazid to acid-labile isoniazid: a study in Finnish Lapland.

Authors:  G A Ellard; P T Gammon; H Tiitinen
Journal:  Tubercle       Date:  1973-09

5.  Inactivation of isoniazid by condensation in a syrup preparation.

Authors:  K V Rao; S Kailasam; N K Menon; S Radhakrishna
Journal:  Bull World Health Organ       Date:  1971       Impact factor: 9.408

6.  Some alterations in the pattern of drug metabolism aociated with pegnancy, oral contraceptives, and the newly-born.

Authors:  J S Crawford; S Rudofsky
Journal:  Br J Anaesth       Date:  1966-06       Impact factor: 9.166

7.  Effect of corticosteroids on blood salicylate concentration.

Authors:  J R Klinenberg; F Miller
Journal:  JAMA       Date:  1965-11-08       Impact factor: 56.272

8.  Kinetics of rifampicin and isoniazid administered alone and in combination to normal subjects and patients with liver disease.

Authors:  G Acocella; L Bonollo; M Garimoldi; M Mainardi; L T Tenconi; F B Nicolis
Journal:  Gut       Date:  1972-01       Impact factor: 23.059

9.  Effect of steroid hormone on activation of Endoxan (cyclophosphamide).

Authors:  T Hayakawa; N Kanai; R Yamada; R Kuroda; H Higashi; H Mogami; D Jinnai
Journal:  Biochem Pharmacol       Date:  1969-01       Impact factor: 5.858

10.  Changes in cortisol metabolism following rifampicin therapy.

Authors:  O M Edwards; R J Courtenay-Evans; J M Galley; J Hunter; A D Tait
Journal:  Lancet       Date:  1974-09-07       Impact factor: 79.321

View more
  14 in total

Review 1.  Ethnic differences in drug disposition and responsiveness.

Authors:  A J Wood; H H Zhou
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

2.  Acetylator polymorphism in Parkinson's disease.

Authors:  J M Ladero; F J Jimenez; J Benitez; M J Fernandez-Gundin; C Martinez; A Llerena; J Cobaleda; J J Muñoz
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 3.  Clinically significant interactions with drugs used in the treatment of tuberculosis.

Authors:  W W Yew
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

4.  Effect of intra-articular glucocorticoids on the disposition of sulphadimidine in chronic osteoarthritis patients.

Authors:  P T Reeves; P Hanrahan; J Edelman; K F Ilett
Journal:  Br J Clin Pharmacol       Date:  1988-11       Impact factor: 4.335

5.  Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations.

Authors:  S Thee; J A Seddon; P R Donald; H I Seifart; C J Werely; A C Hesseling; B Rosenkranz; S Roll; K Magdorf; H S Schaaf
Journal:  Antimicrob Agents Chemother       Date:  2011-10-03       Impact factor: 5.191

Review 6.  Tuberculosis of the central nervous system in immunocompromised patients: HIV infection and solid organ transplant recipients.

Authors:  Christina A Nelson; Joseph R Zunt
Journal:  Clin Infect Dis       Date:  2011-09-29       Impact factor: 9.079

Review 7.  Clinical pharmacokinetics and pharmacodynamics of prednisolone and prednisone in solid organ transplantation.

Authors:  Troels K Bergmann; Katherine A Barraclough; Katie J Lee; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2012-11       Impact factor: 6.447

Review 8.  Pharmacokinetic interactions with rifampicin : clinical relevance.

Authors:  Mikko Niemi; Janne T Backman; Martin F Fromm; Pertti J Neuvonen; Kari T Kivistö
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 9.  Clinically significant drug interactions with antituberculosis agents.

Authors:  J M Grange; P A Winstanley; P D Davies
Journal:  Drug Saf       Date:  1994-10       Impact factor: 5.606

Review 10.  Genetically determined variability in acetylation and oxidation. Therapeutic implications.

Authors:  D W Clark
Journal:  Drugs       Date:  1985-04       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.